ストックスクリーナーアプリを入手
0.9851
10.00%
0.0896
前日終値:
$0.8955
開ける：
$0.93
24時間の取引高:
62,541
Relative Volume:
0.72
時価総額：
$44.79M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-48.43%
1か月 パフォーマンス:
-42.39%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$0.9251
$1.01
1週間の範囲:
$0.8603
$2.02
52週間の値動き範囲:
$0.8603
$4.00
Advanced Biomed Inc Stock (ADVB) Company Profile
ADVB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ADVB
Advanced Biomed Inc
|
0.9851 | 44.79M | 0 | 0 | 0 | 0.00 |
|
TMO
Thermo Fisher Scientific Inc
|
429.81 | 159.40B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
197.25 | 136.01B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
505.44 | 38.21B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
115.11 | 30.90B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IQV
Iqvia Holdings Inc
|
152.19 | 26.35B | 15.50B | 1.33B | 2.16B | 7.34 |
Advanced Biomed Inc (ADVB) 最新ニュース
Financing Quarterly Statistics, Q1 2025 - insights.citeline.com
Biomedical Engineering Courses: Admission 2025, Fees, Eligibility, Entrance Exams, Syllabus/Subjects, Top Colleges, Career Scope & Salary - Shiksha
Harbour BioMed Reports Full Year 2024 Financial Results - Yahoo Finance
Mainz enrols first subject in study to evaluate colorectal cancer test - Yahoo Finance
Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study - Yahoo Finance
Advanced Instruments to Acquire and Merge with Nova Biomedical - Contract Pharma
Harbour BioMed Launches Élancé Therapeutics to Advance Next-Generation Obesity Therapies - PR Newswire
Advanced Biomed Inc. Completes Successful IPO Launch - TipRanks
Revolutionizing Biomedical Research: Unveiling the Power of Microphysiological Systems with Advanced Assays, Integrated Sensor Technologies, and Real-Time Monitoring - ACS Publications
Why Checkpoint Therapeutics Shares Are Trading Higher By Around 66%; Here Are 20 Stocks Moving Premarket - Benzinga
Red-hot market supports two med-tech IPOs in a day - BioWorld Online
A Dynamic Duo: Travis Stancil and Natella Devitskya Celebrate Five Years of Captivating Performances - The Manila Times
Advanced Biomed Inc. Announces Closing of Initial Public Offering Raising $6.56 Million - Nasdaq
Advanced Biomed Inc. Announces Closing Of US$6.56 Million Initial Public Offering - Morningstar
Advanced Biomed prices IPO at $4 per share - MSN
Advanced Biomed Prices 1.6 Million Shares to Raise $6.6 Million in IPO - MarketScreener
OverDrive Appoints Eric Miller to Lead the Company's Data and Information Science Services - The Manila Times
ADVB IPO NewsTaiwanese diagnostics developer Advanced Biomed prices downsized US IPO at the $4 low end - Renaissance Capital
Advanced Biomed Inc. Announces Pricing of Initial Public Offering - GlobeNewswire
This Cancer Detection Biotech Just Priced Its Nasdaq IPOKey Details Inside - StockTitan
Can Mainz Biomed's 82% Detection Rate Technology Revolutionize Colorectal Cancer Prevention? - StockTitan
IPO Roundup: Advanced Biomed, Brag House Holdings and more - MSN
HBM Alpha Therapeutics Enters Strategic Collaboration and License Agreement to Advance Novel Endocrine Therapies - BioSpace
Harbour BioMed and Insilico Medicine Achieve Strategic Collaboration to Advance AI-Driven Antibody Discovery and Development - PR Newswire
Ocean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer and Plans for FDA Alignment on Next-Stage Development - GlobeNewswire
Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population - Yahoo Finance
Moderna Secures $590M Funding From U.S. Government for Bird Flu Jab - Yahoo Finance
NVIDIA Partners With Industry Leaders to Advance Genomics, Drug Discovery and Healthcare - NVIDIA Newsroom
Anaconda Biomed Appoints Trent Reutiman New CEO - Business Wire
Orchestra BioMed shares get shot in the arm on solid clinical trial data - Mugglehead Magazine
Mainz Biomed Enters Agreement with Quest Diagnostics to Advance ColoAlert Colorectal Cancer Screening Test - Nasdaq
Fluid Biomed Inc. Raises $27 Million USD in Oversubscribed Series A Financing to Advance World’s First Bioabsorbable Polymer-Based Stent To Treat Brain Aneurysms - Business Wire
Advanced Biomedical Material Design to Toxicity - ResearchGate
Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific - Benzinga
Thermo Fisher Scientific and Mainz Biomed Partner to Advance Colorectal Cancer Screening Technology - citybuzz -
Mainz Biomed Partners with Thermo Fisher to Advance Colorectal Cancer Screening - Contract Pharma
Shire Plans San Diego Campus - Site Selection Magazine
L&K BIOMED Announces FDA Approval of the BluEX Lumbar Expandable Cage System, Featuring Advanced Surface Technology for Comprehensive Spine Interbody Fusion Options. - Becker's Spine Review
Advanced Biomed dramatically downsizes proposed IPO to $9.4M - MSN
Taiwanese diagnostics developer Advanced Biomed slashes deal size by 92% ahead of $9 million US IPO - renaissancecapital.com
Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update - Yahoo Finance
Thermoelectric Materials and Devices for Advanced Biomedical ApplicationsJia2024Small - Wiley Online Library
Harbour BioMed Announces Publication of the Phase I Study Results for Porustobart in Combination with Toripalimab in Advanced Melanoma and Other Solid Tumors - digitalmore.co
Roche and BARDA: partnering for better brain health - Roche
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025 - Stock Titan
AskBio and Belief BioMed partner to advance gene therapies - Pharmaceutical Technology
AskBio to collaborate with Belief BioMed to explore the potential of new gene therapies - Bayer
Curi Bio’s Growth Propels Move to Prime Seattle Location to Advance Cutting-Edge Drug Discovery Research - Business Wire
(PDF) Polysaccharide-Based Hydrogels for Advanced Biomedical Engineering Applications - ResearchGate
Polysaccharide-Based Hydrogels for Advanced Biomedical Engineering Applications - ACS Publications
Medical Device Maker Nova Biomedical Is Exploring a Sale - BNN Bloomberg
Advanced Biomed Inc (ADVB) 財務データ
Advanced Biomed Inc (ADVB) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
0.94%
2.86%
大文字化:
|
ボリューム (24 時間):